View Older Stories View More Recent Stories
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Citi on Hims and Hers (HIMS): 'If HIMS does end up partnering with LLY, in our view it would signal that HIMS is “throwing in the towel” on compounded GLP-1s'
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
EMA says Ozempic, Wegovy may cause rare eye condition
-
TD Cowen Revisits Eli Lilly's (LLY) Surpass-CVOT Expectations, Lowers Stock PT
-
Erste Group Downgrades Eli Lilly (LLY) to Hold
-
Morgan Stanley weighs in on Eli Lilly (LLY) into SURPASS-CVOT phrase 3 data
-
Wegovy Use Up 50% Among Us Teens - Reuters
-
Eli Lilly & Co. (LLY) presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer
-
Eli Lilly & Co. (LLY) announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics
-
What can get the U.S. large-cap pharma sector to work?
-
Eli Lilly & Co. (LLY) gives presentation highlights for 2025 ASCO
-
Morgan Stanley weighs in on Eli Lilly (LLY) following Cigna GLP-1 news
-
Lilly (LLY) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
-
Truist: 'we share some interesting takeaways from the ruling that could provide a read through on the Wegovy/Ozempic case'
-
Bernstein: 'Softer Week for Total Scripts, but Eli Lilly (LLY) Still Gains Share'
-
Bernstein Sees Eli Lilly (LLY) in 'Stronger Position Relative to Peers' Following Trump's Executive Order
-
Trump discusses price gouging of 'fat drugs' in the U.S.
-
Trump says drug prices to be cut by 59%
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Eli Lilly & Co. (LLY) to expand Purdue University collaboration with up to a $250M investment to accelerate pharmaceutical innovation
-
Eli Lilly & Co. (LLY) Announces Leaderhsip Changes
-
Trump to pitch sweeping Medicare drug price plan - Politico
-
Eli Lilly & Co. (LLY) option IV flat
-
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield
-
Hims & Hers is due to report after the bell on Monday. Here's what to expect
-
Novo Nordisk shares jump as FDA accepts oral Wegovy application
-
Eli Lilly (LLY) PT Lowered to $1,050 at UBS
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) sell-off 'overdone' on CVS move on Wegovy - Leerink
-
Eli Lilly & Co. (LLY) Misses Q1 EPS by 12c; updates guidance
-
Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.2 puts into quarter results
-
Eli Lilly & Co. (LLY) May 2 weekly 885 straddle priced into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put into quarter results
-
Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk
-
Eli Lilly & Co. (LLY) option implied volatility flat into quarter results
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Goldman Sachs Reiterates Buy Rating on Eli Lilly (LLY)
-
HSBC Downgrades Eli Lilly (LLY) to Reduce
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Bernstein on Eli Lilly (LLY): 'Our Top Pick Still Holds'
-
Cantor Fitzgerald Starts Eli Lilly (LLY) at Overweight
-
BMO Capital: 'Eli Lilly (LLY) Positions Orforglipron for a Global Launch'
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put as share price up 15.9%
-
Eli Lilly (LLY) PT Lowered to $900 at BMO Capital

